• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary.

作者信息

Endrei Dóra, Molics Bálint, Agoston István

机构信息

Faculty of Health Sciences, Institute for Health Insurance University of Pécs, Pécs, Hungary; Clinical Center, University of Pécs, Pécs, Hungary.

Faculty of Health Sciences, Institute for Health Insurance University of Pécs, Pécs, Hungary.

出版信息

Value Health. 2014 Jun;17(4):487-9. doi: 10.1016/j.jval.2014.01.011. Epub 2014 Apr 29.

DOI:10.1016/j.jval.2014.01.011
PMID:24969012
Abstract
摘要

相似文献

1
Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary.新型医疗技术报销中的多标准决策分析：来自匈牙利的实际经验。
Value Health. 2014 Jun;17(4):487-9. doi: 10.1016/j.jval.2014.01.011. Epub 2014 Apr 29.
2
A pilot study of multicriteria decision analysis for valuing orphan medicines.多准则决策分析在评估孤儿药价值中的初步研究。
Value Health. 2013 Dec;16(8):1163-9. doi: 10.1016/j.jval.2013.10.002. Epub 2013 Nov 14.
3
International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.用于评估孤儿药的多标准决策分析（MCDA）的国际经验：一项范围综述。
Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):409-420. doi: 10.1080/14737167.2019.1633918. Epub 2019 Jul 1.
4
Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.当前的成本效果阈值是否过时？个性化医疗时代的药品价值评估。
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):435-7. doi: 10.1080/14737167.2016.1180980. Epub 2016 May 6.
5
Treacle and Smallpox: Two Tests for Multicriteria Decision Analysis Models in Health Technology Assessment.糖浆与天花：卫生技术评估中多标准决策分析模型的两项测试
Value Health. 2017 Mar;20(3):512-515. doi: 10.1016/j.jval.2016.10.005. Epub 2016 Dec 20.
6
Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.加拿大孤儿药常见药物评估建议：建议基础及与魁北克、澳大利亚、苏格兰和新西兰相似评估的比较。
Orphanet J Rare Dis. 2018 Jan 30;13(1):27. doi: 10.1186/s13023-018-0759-9.
7
Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.洞察保加利亚报销决策标准：对孤儿药的影响。
Folia Med (Plovdiv). 2013 Jul-Dec;55(3-4):80-6. doi: 10.2478/folmed-2013-0032.
8
SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT.卫生技术评估中孤儿药的科学与社会价值判断
Int J Technol Assess Health Care. 2016 Jan;32(4):218-232. doi: 10.1017/S0266462316000416. Epub 2016 Sep 14.
9
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.为何针对相同药物的卫生技术评估覆盖建议在不同地区存在差异？应用混合方法框架对四个欧洲国家的罕见病药物决策进行系统比较。
Eur J Health Econ. 2017 Jul;18(6):715-730. doi: 10.1007/s10198-016-0823-0. Epub 2016 Aug 18.
10
Using multi-criteria decision analysis to appraise orphan drugs: a systematic review.运用多标准决策分析评估罕见病药物：一项系统综述
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):135-146. doi: 10.1080/14737167.2018.1414603. Epub 2017 Dec 20.

引用本文的文献

1
The relative importance of severity and rarity criteria in health resource allocation: an umbrella review.严重程度和罕见程度标准在卫生资源配置中的相对重要性：伞式审查。
Int J Technol Assess Health Care. 2024 Nov 14;40(1):e54. doi: 10.1017/S0266462324004653.
2
Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus.克服医院健康技术评估（HB-HTA）中的障碍：国际专家小组共识
Healthcare (Basel). 2024 Apr 25;12(9):889. doi: 10.3390/healthcare12090889.
3
Comparative analysis of the quality of life regarding patients who underwent hip replacement in public versus private hospitals in Hungary.
比较分析在匈牙利公立医院和私立医院接受髋关节置换手术的患者的生活质量。
Sci Rep. 2024 May 1;14(1):10031. doi: 10.1038/s41598-024-60720-4.
4
Ensemble Deep Learning Derived from Transfer Learning for Classification of COVID-19 Patients on Hybrid Deep-Learning-Based Lung Segmentation: A Data Augmentation and Balancing Framework.基于迁移学习的集成深度学习用于基于混合深度学习的肺部分割对新冠肺炎患者进行分类：一种数据增强与平衡框架
Diagnostics (Basel). 2023 Jun 2;13(11):1954. doi: 10.3390/diagnostics13111954.
5
The long-term effect of generic price competition on the Hungarian statin market.仿制药价格竞争对匈牙利他汀类药物市场的长期影响。
BMC Health Serv Res. 2023 May 6;23(1):447. doi: 10.1186/s12913-023-09431-6.
6
Disease-Specific Quality of Life among Patients with Peripheral Artery Disease in Hungary.匈牙利外周动脉疾病患者的疾病特异性生活质量。
Int J Environ Res Public Health. 2023 Feb 17;20(4):3558. doi: 10.3390/ijerph20043558.
7
Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods.罕见病患者体验价值要素框架：一项展示定性和定量方法相结合适用性的案例研究
Pharmacoecon Open. 2023 Mar;7(2):217-228. doi: 10.1007/s41669-022-00376-w. Epub 2022 Nov 1.
8
Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.增值药物核心评估框架的制定：药物政策视角报告2
Cost Eff Resour Alloc. 2021 Jul 15;19(1):42. doi: 10.1186/s12962-021-00296-2.
9
Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.多标准决策分析和价值框架中用于评估罕见病疗法的标准及评分函数：一项系统文献综述
Pharmacoecon Open. 2021 Dec;5(4):605-612. doi: 10.1007/s41669-021-00271-w. Epub 2021 May 18.
10
Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.支持中高收入国家创新药物评估的框架潜在标准——关于价值框架和多标准决策分析的系统文献综述
Front Pharmacol. 2020 Aug 14;11:1203. doi: 10.3389/fphar.2020.01203. eCollection 2020.